Mangoceuticals (NASDAQ:MGRX) Upgraded at Wall Street Zen

Mangoceuticals (NASDAQ:MGRX) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mangoceuticals in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Mangoceuticals currently has an average rating of “Sell”.

Mangoceuticals Price Performance

MGRX opened at $0.43 on Friday. The stock has a market capitalization of $7.38 million, a price-to-earnings ratio of -0.29 and a beta of 2.12. The business has a 50-day moving average of $0.39 and a two-hundred day moving average of $0.63. Mangoceuticals has a 12 month low of $0.16 and a 12 month high of $2.75.

Mangoceuticals (NASDAQ:MGRX) last posted its quarterly earnings results on Tuesday, May 19th. The company reported ($0.22) EPS for the quarter. The business had revenue of $0.07 million during the quarter. Mangoceuticals had a negative net margin of 4,639.13% and a negative return on equity of 112.00%.

Institutional Trading of Mangoceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC purchased a new stake in Mangoceuticals in the 4th quarter valued at about $1,137,000. Ikarian Capital LLC purchased a new stake in shares of Mangoceuticals during the 4th quarter worth about $102,000. Jane Street Group LLC acquired a new stake in Mangoceuticals during the 4th quarter worth approximately $35,000. Boothbay Fund Management LLC acquired a new stake in Mangoceuticals during the 4th quarter worth approximately $28,000. Finally, Virtu Financial LLC acquired a new stake in Mangoceuticals during the 4th quarter worth approximately $25,000. Hedge funds and other institutional investors own 56.72% of the company’s stock.

About Mangoceuticals

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.